title: [Multiparametric flow cytometry analyzes the expressions of immunophenotype CD133, CD34, CD44 in lung cancer naive cells].
abstract: OBJECTIVE
  To study the expression of CD133, CD34 and CD44 in lung cancer, and distribution of cell subpopulations that generated by combination of different markers.
  
  
  METHODS
  By collecting 10 normal lung tissues and 40 lung cancer fresh samples that were diagnosed pathologically, preparing single cell suspension, and labelling cells with CD133, CD34, CD44, CD117, CD43, CD45 and LIN(CD2, CD3, CD31, CD64) monoclone antibodies, we analyzed the distribution of the above-mentioned antibodies in lung cancer cells on FCM. By double-parameters plots, we analyzed the naive cell subpopulations that were generated through combination of positive and negative antigen expression.
  
  
  RESULTS
  In lung cancer parenchymal-cells (LIN- CD45-) expressed CD133, CD34 and CD44 dim positive and, expressed CD117 and CD43 negative. The mann-Whitney rank test results shows that there was no significant difference for the expression of CD133, CD34, CD44 between lung cancer and normal lung tissue, and CD44+, CD133- CD34-, CD133+ CD44+, CD133+ CD44-, CD133+ CD34+, CD133- CD34+ and CD133- CD44+ expressed differently (P < 0.05) between lung adenocarcinoma and lung squamous cell carcinoma. The cluster analysis results suggest that they are classified to 4 subsets.
  
  
  CONCLUSIONS
  CD133, CD34, CD44 could be the marker of lung cancer naive cells, which could contribute to study lung cancer cell development.
authors.affiliation: Department of Respiratory Medicine, Laboratory Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Suchian University, Chengdu, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Liu
authors.forename: Wei-min
authors.initials: WM
authors.lastname: Li
authors.forename: Xian-ming
authors.initials: XM
authors.lastname: Mo
authors.forename: Lun-xu
authors.initials: LX
authors.lastname: Liu
authors.forename: Yun
authors.initials: Y
authors.lastname: Wang
authors.forename: Guo-wei
authors.initials: GW
authors.lastname: Che
authors.forename: Zhu
authors.initials: Z
authors.lastname: Wu
authors.forename: Ji-long
authors.initials: JL
authors.lastname: Gou
mesh_terms: D000071916:AC133 Antigen; D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology; D015703:Antigens, CD / Q000096:biosynthesis*; D018952:Antigens, CD34 / Q000096:biosynthesis*; D014408:Biomarkers, Tumor; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000473:pathology; D005260:Female; D006023:Glycoproteins / Q000096:biosynthesis*; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis*; D016130:Immunophenotyping; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology; D008297:Male; D014411:Neoplastic Stem Cells / Q000276:immunology*; D010455:Peptides
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D006023:Glycoproteins; D018960:Hyaluronan Receptors; C000606023:PROM1 protein, human; D010455:Peptides